Two doses of a simple tuberculosis vaccine after surgery support the immune system in fighting cancer cells and could significantly improve treatment outcomes for the most common form of bladder cancer, according to a pilot study involving 40 patients. Initial results of the RUTIVAC-1 study were presented at EAU25.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Alopecia areata in children, adolescents, and adults
New Guideline Classifies the Evidence Base for Topical and Systemic Therapies
- Cardiology and Nutrition
Ultra-Processed Foods and Cardiovascular Risk—The New AHA Position
- Actinic keratoses
Targeted Treatment of Multiple AK Lesions—Balancing Efficacy and Convenience
- Obesity: A Multimodal and Interdisciplinary Approach
New Swiss Clinical Practice Guideline Provides Guidance
- cSCC: Personalizing Treatment Strategies and Follow-up Care Plans
Comprehensive risk stratification is no simple matter: what’s new?
- Baxdrostat – a new class of drugs for treating difficult-to-control hypertension
First Aldosterone Synthase Inhibitor Is Here
- Geriatric Small-Cell Lung Cancer
Therapeutic Challenges
- Chronic Pruritus in Renal, Hepatic, and Biliary Tract Diseases